diet pill

Orexigen Therapeutics has announced that encouraging interim results from the Light Study evaluating the cardiovascular risks of combination naltrexone/bupropion, indicated for weight loss in obese patients, have prompted resubmission of a new drug application to the FDA., according to a press...